# EDGAR Filing Document

**Accession Number:** 0001054905
**File Stem:** 0001193125-25-265585
**Filing Date:** 2025-11
**Character Count:** 32815
**Document Hash:** 04337d8ed372ddd8ccc0b9c47f5f2dc3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-265585.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001193125-25-265585

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251104

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INNOSPEC INC.
- **CENTRAL INDEX KEY:** 0001054905
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 981081725
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13879
- **FILM NUMBER:** 251451587

**BUSINESS ADDRESS:**
- **STREET 1:** 8310 SOUTH VALLEY HIGHWAY
- **STREET 2:** SUITE 350
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112
- **BUSINESS PHONE:** 7203556451

**MAIL ADDRESS:**
- **STREET 1:** 8310 SOUTH VALLEY HIGHWAY
- **STREET 2:** SUITE 350
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OCTEL CORP
- **DATE OF NAME CHANGE:** 19980209

?xml version='1.0' encoding='ASCII'? 8-K

#### UNITED STATES

#### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### Form 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): November 4, 2025

### INNOSPEC INC.

#### (Exact name of registrant as specified in its charter)

#### Commission File Number: 1-13879

---

| | |
|:---|:---|
| **Delaware** | **98-0181725** |
| **(State or other jurisdiction of** | **(IRS Employer** |
| **incorporation)** | **Identification No.)** |

---

#### 8310 South Valley Highway, Suite 350

#### Englewood, Colorado, 80112

#### (Address of principal executive offices, including zip code)

#### (303)792-5554

#### (Registrant's telephone number, including area code)

#### (Former name or former address, if changed since last report)
**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

**[ ]** **Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**

**[ ]** **Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**

**[ ]** **Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**

**[ ]** **Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).**

#### Emerging growth company [ ]
**If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [ ]**

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Title of each class** | **Trading Symbol(s)** | **Name of exchange on which**<br> **registered** |
| &nbsp;&nbsp;&nbsp;**Common Stock** | **IOSP** | **NASDAQ** |

---

------

#### Item 2.02 Results of Operations and Financial Condition.
On November 4, 2025, Innospec Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025 (the "Press Release").

#### Item 7.01 Regulation FD Disclosure
The Press Release also announced that on November 2, 2025, the Company's Board of Directors declared a semi-annual dividend of $0.87 per share on the Company's common stock (IOSP). The dividend will be paid on November 26, 2025, to holders of record on November 18, 2025.

#### Item 9.01. Financial Statements and Exhibits.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

#### EXHIBIT INDEX

---

| | | |
|:---|:---|:---|
| Number | Description | Method of Filing |
| 99.1 | [Press Release dated November 4, 2025, announcing Innospec Inc.'s financial results for the fiscal quarter ended September 30, 2025](d88595dex991.htm) | Filed Herewith |
| 104 | Cover Page Interactive Data File – the cover page XBRL tags are embedded<br> within the Inline XBRL document. |  |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | INNOSPEC INC.<br>|
| Date: November 5, 2025 | By: | ***/s/ David B. Jones***<br>|
|  |  | **David B. Jones** |
|  |  | **Senior Vice President, General Counsel and**<br> **Chief Compliance Officer** |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g88595g1031204249642.jpg)

![LOGO](g88595g1031204249861.jpg)

**INNOSPEC REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS** 

***Continued strength in Fuel Specialties offsetting lower than expected results in our other business segments***

***Focused on delivering sequential gross margin and operating income growth in Performance Chemicals and Oilfield Services***

***Strong cash flow of $39.3 million generated from operations; Net cash improves to $270.8 million***

***GAAP EPS 52 cents per share and adjusted non-GAAP EPS $1.12***

***Semi Annual dividend increased by 10 percent: $10.7 million in share repurchases made in the quarter***

**Englewood, CO – November 4, 2025** – Innospec Inc. (NASDAQ: IOSP) today announced its financial results for the third quarter ended September 30, 2025 and declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025. This brings the annual dividend to $1.71 per share, a 10 percent increase over 2024.

Total revenues for the third quarter were $441.9 million, similar to $443.4 million in the corresponding period last year. Net income for the quarter was $12.9 million or 52 cents per diluted share, compared to $33.4 million or $1.33 per diluted share recorded last year.

Our headline results for the quarter include $24.4 million in charges, which had a negative EPS impact of 57 cents. These charges are composed of $42.9 million of asset and intangible impairments and restructuring charges related to the expected lack of near-term recovery in QGP, our Mexican oilfield production business and our US stimulation business, offset by an $18.5 million reduction to the fair value of contingent consideration associated with the 2023 acquisition of QGP.

Adjusted EBITDA for the quarter was $44.2 million compared to $50.5 million reported in the same period a year ago. Innospec generated cash from operating activities of $39.3 million, before capital expenditures of $22.2 million in the quarter. The quarter closed with net cash of $270.8 million.

Results for this quarter include some special items, which are summarized in the table below. Excluding these items, adjusted non-GAAP EPS in the third quarter was $1.12 per diluted share, compared to $1.35 per diluted share a year ago.

Adjusted EBITDA, income before income taxes excluding special items and net income excluding special items and related per-share amounts together with net cash, are non-GAAP financial measures that are defined and reconciled with GAAP results herein and in the schedules below.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **<u>Quarter ended September 30, 2025</u>** | **<u>Quarter ended September 30, 2025</u>** | **<u>Quarter ended September 30, 2025</u>** | **<u>Quarter ended September 30, 2024</u>** | **<u>Quarter ended September 30, 2024</u>** | **<u>Quarter ended September 30, 2024</u>** |
| **<u>(in millions, except share and per share data)</u>** | **<u>Income<br>before</u>**<br> **<u>income<br>taxes</u>** | **<u>Net</u>**<br> **<u>income</u>** | **<u>Diluted<br>EPS</u>** | **<u>Income<br>before</u>**<br> **<u>income<br>taxes</u>** | **<u>Net<br>income</u>** | **<u>Diluted<br>EPS</u>** |
|  **Reported GAAP amounts** | $**11.5** | $**12.9** | $**0.52** | $**44.8** | $**33.4** | $**1.33** |
|  Impairment of property, plant and equipment | 22.9 | 18.1 | 0.73 |  |  |  |
|  Adjustment to fair value of contingent consideration | (17.7) | (17.7) | (0.71) | 0.7 | 0.5 | 0.02 |
|  Impairment of intangible assets | 19.1 | 14 | 0.56 |  |  |  |
|  Foreign currency exchange losses/(gains) | (3.2) | (2.4) | (0.10) | 4.1 | 3.1 | 0.12 |
|  Amortization of acquired intangible assets | 2.2 | 1.7 | 0.07 | 3 | 2.3 | 0.09 |
|  Legacy costs of closed operations | 1 | 0.8 | 0.03 | 1 | 0.8 | 0.03 |
|  Restructuring charge | 0.9 | 0.6 | 0.02 |  |  |  |
|  Recovery of historical pension costs |  |  |  | (8.4) | (6.3) | (0.25) |
|  Settlement of historical tax audits |  |  |  |  | 1.3 | 0.05 |
|  Adjustment of income tax provisions |  |  |  |  | (0.9) | (0.04) |
|  | 25.2 | 15.1 | 0.60 | 0.4 | 0.8 | 0.02 |
|  **Adjusted non-GAAP amounts** | $**36.7** | $**28.0** | $**1.12** | $**45.2** | $**34.2** | $**1.35** |

---

Commenting on the third quarter results, Patrick S. Williams, President and Chief Executive Officer, said,

"This was a mixed quarter for Innospec with continued strong operating income growth and margin expansion in Fuel Specialties, offsetting lower results in Performance Chemicals and Oilfield Services.

Performance Chemicals sales grew on the prior year; however, gross margins declined as expected on higher costs, price management and weaker product mix. While these results are below our expectations, margin actions are beginning to take effect, and we are optimistic that this will drive sequential improvement in the fourth quarter. Delivering sustainable margin improvement remains the primary focus of the business team.

Fuel Specialties had another strong quarter with improved gross margins and a double-digit increase in operating income over the prior year. As expected, the business has continued to deliver consistent results.

Oilfield Services operating income declined sequentially and versus the prior year on lower than anticipated Middle East activity due to timing and phasing. We are optimistic that we will deliver sequential operating income and margin improvement in the fourth quarter as Middle East activity returns, our new DRA expansion comes online and our focus on margin improvement continues. Our outlook does not assume any resumption of Mexican sales."

Revenues in Performance Chemicals of $170.8 million were up 4 percent over the third quarter of last year. Volumes fell by 2 percent offset by a positive price/mix of 3 percent and favorable currency impact of 3 percent. Gross margins of 15.1 percent decreased by 7.0 percentage points from the same quarter last year. Operating income of $9.2 million decreased 54 percent from $20.0 million in the prior year period.

Revenues in Fuel Specialties of $172.0 million were up 4 percent from $165.8 million in the third quarter of last year. Volumes were down 7 percent offset by a positive price/mix of 7 percent and favorable currency impact of 4 percent. Gross margins of 35.6 percent increased by 2.0 percentage points over last year. Operating income of $35.3 million was up 14 percent from $30.9 million a year ago.

Revenues in Oilfield Services of $99.1 million for the quarter were down 13 percent from $114.0 million in the third quarter of last year. Gross margins of 30.0 percent increased by 1.7 percentage points from the same quarter last year on a richer sales mix. Operating income of $4.8 million decreased 32 percent from $7.1 million in the prior year period.

------

Corporate costs for the quarter were $18.2 million, compared with $11.8 million a year ago which included an $8.4 million recovery of historic pension costs. The adjusted effective tax rate for the quarter was 22.5 percent compared to 24.6 percent in the same period last year, due to the geographical mix of taxable profits.

For the quarter, cash provided by operating activities was $39.3 million compared to $73.5 million a year ago. As of September 30, 2025, Innospec had $270.8 million in cash and cash equivalents and no debt.

Mr. Williams concluded,

"We continue to prioritize gross margin and operating income improvement in Performance Chemicals and Oilfield Services. In both segments, we are optimistic that we will deliver sequential growth in the coming quarters. We remain focused on a combination of sales, price/cost actions, new technology commercialization and other improvement opportunities. In addition, we expect Fuel Specialties to continue to deliver strong results.

Operating cash generation was again positive in the quarter, and our net cash position closed at over $270 million. We have significant balance sheet flexibility for M&A, dividend growth, organic investment and buybacks. This quarter our Board approved a further 10 percent increase in our semi-annual dividend to 87 cents per share, and we continued our record of returning value to shareholders with $10.7 million in share repurchases."

**Use of Non-GAAP Financial Measures** 

The information presented in this press release includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise adjusted EBITDA, income before income taxes excluding special items, net income excluding special items and related per share amounts together with net cash. Adjusted EBITDA is net income per our consolidated financial statements adjusted for the exclusion of interest income, net, income taxes, depreciation and amortization, recovery of historical pension costs, foreign currency exchange (gains)/losses, legacy costs of closed operations, adjustment to fair value of contingent consideration, restructuring charge, impairment of property, plant and equipment and impairment of intangible assets. Income before income taxes, net income and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of impairment of property, plant and equipment, adjustment to fair value of contingent consideration, impairment of intangible assets, foreign currency exchange (gains)/losses, amortization of acquired intangible assets, legacy costs of closed operations, restructuring charge, recovery of historical pension costs, settlement of historical tax audits and adjustment of income tax provisions. Net cash is cash and cash equivalents less total debt. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the schedules below. The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company's underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company's performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company's performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and net income excluding special items and adjusted EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income) to allocate resources and evaluate the performance of the Company's operations and has provided a reconciliation of adjusted EBITDA and net income excluding special items, and related per share amounts, to GAAP net income herein and in the schedules below.

**About Innospec Inc.** 

Innospec Inc. is an international specialty chemicals company with approximately 2,450 employees in 22 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care, Home Care, Agrochemical, Mining and Industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil and gas exploration and production industry.

------

**Forward-Looking Statements** 

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like "expects," "estimates," "anticipates," "may," "could," "believes," "feels," "plans," "intends," "outlook" or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec's Annual Report on Form 10-K for the year ended December 31, 2024, Innospec's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors" in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contacts:** 

Corbin Barnes

Innospec Inc.

+44-151-355-3611

corbin.barnes@innospecinc.com

------

**INNOSPEC INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME** 

Schedule 1

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **(in millions, except share and per share data)** | **Three Months Ended**<br>**September 30** | **Three Months Ended**<br>**September 30** | **Three Months Ended**<br>**September 30** | **Three Months Ended**<br>**September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** |
| **(in millions, except share and per share data)** | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|  Net sales | $— | 441.9 | $— | 443.4 | $— | 1322.4 | $— | 1378.6 |
|  Cost of goods sold |  | (325.2) |  | (319.3) |  | (957.4) |  | (971.9) |
|  Gross profit |  | 116.7 |  | 124.1 |  | 365.0 |  | 406.7 |
|  Operating expenses: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Selling, general and administrative |  | (71.9) |  | (64.3) |  | (215.8) |  | (226.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development |  | (13.7) |  | (13.6) |  | (40.0) |  | (41.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjustment to fair value of contingent consideration |  | 17.7 |  | (0.7) |  | 16.2 |  | (2.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charge |  | (0.9) |  |  |  | (0.9) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment of property, plant and equipment |  | (22.9) |  |  |  | (22.9) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment of intangible assets |  | (19.1) |  |  |  | (19.1) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Profit on disposal of property, plant and equipment |  |  |  | 0.1 |  | 0.2 |  | 0.2 |
|  Total operating expenses |  | (110.8) |  | (78.5) |  | (282.3) |  | (269.9) |
|  Operating income |  | 5.9 |  | 45.6 |  | 82.7 |  | 136.8 |
|  Other income/(expense), net |  | 3.4 |  | (3.5) |  | (2.2) |  | 0.1 |
|  Interest income, net |  | 2.2 |  | 2.7 |  | 7.3 |  | 6.9 |
|  Income before income taxes |  | 11.5 |  | 44.8 |  | 87.8 |  | 143.8 |
|  Income taxes |  | 1.4 |  | (11.4) |  | (18.6) |  | (37.8) |
|  Net income | $— | 12.9 | $— | 33.4 | $— | 69.2 | $— | 106.0 |
|  Earnings per share: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basic | $— | 0.52 | $— | 1.34 | $— | 2.78 | $— | 4.25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted | $— | 0.52 | $— | 1.33 | $— | 2.76 | $— | 4.22 |
|  Weighted average shares outstanding (in thousands): |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basic |  | 24834 |  | 24941 |  | 24914 |  | 24926 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted |  | 24909 |  | 25101 |  | 25045 |  | 25103 |

---

------

**INNOSPEC INC. AND SUBSIDIARIES** 

Schedule 2A

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| ***SEGMENTAL ANALYSIS OF RESULTS*** | **Three Months Ended<br>September 30** | **Three Months Ended<br>September 30** | **Three Months Ended<br>September 30** | **Three Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** |
| **(in millions)** | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|  Net sales: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Performance Chemicals | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;170.8 | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;163.6 | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;513.0 | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;484.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fuel Specialties |  | 172.0 |  | 165.8 |  | 507.4 |  | 509.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oilfield Services |  | 99.1 |  | 114.0 |  | 302.0 |  | 384.8 |
|  |  | 441.9 |  | 443.4 |  | 1322.4 |  | 1378.6 |
|  Gross profit: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Performance Chemicals |  | 25.8 |  | 36.1 |  | 91.6 |  | 110.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fuel Specialties |  | 61.2 |  | 55.7 |  | 184.9 |  | 173.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oilfield Services |  | 29.7 |  | 32.3 |  | 88.5 |  | 122.8 |
|  |  | 116.7 |  | 124.1 |  | 365.0 |  | 406.7 |
|  Operating income: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Performance Chemicals |  | 9.2 |  | 20.0 |  | 43.3 |  | 62.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fuel Specialties |  | 35.3 |  | 30.9 |  | 107.6 |  | 94.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oilfield Services |  | 4.8 |  | 7.1 |  | 15.1 |  | 31.3 |
|  Corporate costs |  | (18.2) |  | (11.8) |  | (56.8) |  | (49.6) |
|  |  | 31.1 |  | 46.2 |  | 109.2 |  | 138.7 |
|  Adjustment to fair value of contingent consideration |  | 17.7 |  | (0.7) |  | 16.2 |  | (2.1) |
|  Restructuring charge |  | (0.9) |  | &nbsp;&nbsp;&nbsp;&nbsp;- |  | (0.9) |  | &nbsp;&nbsp;&nbsp;&nbsp;- |
|  Impairment of property, plant and equipment |  | (22.9) |  | &nbsp;&nbsp;&nbsp;&nbsp;- |  | (22.9) |  | &nbsp;&nbsp;&nbsp;&nbsp;- |
|  Impairment of intangible assets |  | (19.1) |  | &nbsp;&nbsp;&nbsp;&nbsp;- |  | (19.1) |  | &nbsp;&nbsp;&nbsp;&nbsp;- |
|  Profit on disposal of property, plant and equipment |  |  |  | 0.1 |  | 0.2 |  | 0.2 |
|  Total operating income | $— | 5.9 | $— | 45.6 | $— | 82.7 | $— | 136.8 |

---

Schedule 2B

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| ***NON-GAAP MEASURES*** | **Three Months Ended<br>September 30** | **Three Months Ended<br>September 30** | **Three Months Ended<br>September 30** | **Three Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** | **Nine Months Ended<br>September 30** |
| **(in millions)** | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|  Net income | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.9 | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33.4 | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;69.2 | $— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;106 |
|  Interest income, net |  | (2.2) |  | (2.7) |  | (7.3) |  | (6.9) |
|  Income taxes |  | (1.4) |  | 11.4 |  | 18.6 |  | 37.8 |
|  Depreciation and amortization |  | 11.9 |  | 11 |  | 34.2 |  | 32.3 |
|  Recovery of historical pension costs |  |  |  | (8.4) |  |  |  | (8.4) |
|  Foreign currency exchange (gains)/losses |  | (3.2) |  | 4.1 |  | 1.1 |  | 3.1 |
|  Legacy costs of closed operations |  | 1 |  | 1 |  | 4.8 |  | 2.6 |
|  Adjustment to fair value of contingent consideration |  | (17.7) |  | 0.7 |  | (16.2) |  | 2.1 |
|  Restructuring charge |  | 0.9 |  | &nbsp;&nbsp;&nbsp;&nbsp;- |  | 0.9 |  | &nbsp;&nbsp;&nbsp;&nbsp;- |
|  Impairment of property, plant and equipment |  | 22.9 |  | &nbsp;&nbsp;&nbsp;&nbsp;- |  | 22.9 |  | &nbsp;&nbsp;&nbsp;&nbsp;- |
|  Impairment of intangible assets |  | 19.1 |  | &nbsp;&nbsp;&nbsp;&nbsp;- |  | 19.1 |  | &nbsp;&nbsp;&nbsp;&nbsp;- |
|  Adjusted EBITDA |  | 44.2 |  | 50.5 |  | 147.3 |  | 168.6 |

---

------

Schedule 3

**INNOSPEC INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED BALANCE SHEETS** 

---

| | | |
|:---|:---|:---|
| **<u>(in millions)</u>** | **September 30,** <br>**2025** | **December 31,** <br>**2024** |
|  <u>*Assets*</u> |  |  |
|  Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | 270.8 | 289.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trade and other accounts receivable | 349.5 | 341.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | 345.2 | 301.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses | 8.7 | 21.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid income taxes | 10.5 | 3.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other current assets | 4.1 | 0.6 |
|  Total current assets | 988.8 | 956.6 |
|  Net property, plant and equipment | 278.6 | 269.7 |
|  Operating lease right-of-use assets | 49.0 | 44.8 |
|  Goodwill | 399.8 | 382.5 |
|  Other intangible assets | 63.3 | 65.4 |
|  Deferred tax assets | 8.9 | 9.4 |
|  Pension asset |  | 2.4 |
|  Other non-current assets | 11.0 | 3.9 |
|  Total assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1799.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1734.7 |
|  <u>*Liabilities and Stockholders' Equity*</u> |  |  |
|  Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $162.2 | $163.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued liabilities | 167.3 | 169.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Current portion of operating lease liabilities | 16.0 | 13.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Current portion of plant closure provisions | 5.0 | 5.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued income taxes | 5.6 | 19.6 |
|  Total current liabilities | 356.1 | 371.4 |
|  Operating lease liabilities, net of current portion | 33.0 | 31.0 |
|  Plant closure provisions, net of current portion | 63.2 | 55.3 |
|  Deferred tax liabilities | 14.1 | 23.5 |
|  Pension liabilities and post-employment benefits | 13.8 | 13.1 |
|  Acquisition-related contingent consideration | 8.2 | 20.1 |
|  Other non-current liabilities | 8.1 | 4.2 |
|  Equity | 1302.9 | 1216.1 |
|  Total liabilities and equity | 1799.4 | 1734.7 |

---

------

Schedule 4

**INNOSPEC INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended**<br>**September 30** | **Nine Months Ended**<br>**September 30** | **Nine Months Ended**<br>**September 30** | **Nine Months Ended**<br>**September 30** |
| **<u>(in millions)</u>** | **2025** | **2025** | **2024** | **2024** |
|  <u>*Cash Flows from Operating Activities*</u> |  |  |  |  |
|  Net income | $— | 69.2 | $— | 106 |
|  Adjustments to reconcile net income to cash provided by operating activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization |  | 34.2 |  | 32.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjustment to fair value of contingent consideration |  | (14.9) |  | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment of property, plant and equipment |  | 22.9 |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment of intangible assets |  | 19.1 |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred taxes |  | (10.6) |  | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Profit on disposal of property, plant and equipment |  | (0.2) |  | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash movements on defined benefit pension plans |  | 2.6 |  | (2.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock option compensation |  | 5 |  | 6.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in working capital |  | (24.4) |  | 11.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Movements in plant closure provisions |  | 1.1 |  | &nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Movements in income taxes |  | (19.9) |  | 1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Movements in unrecognized tax benefits |  |  |  | (3.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Movements in other assets and liabilities |  | (7.2) |  | 4.2 |
|  Net cash provided by operating activities |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76.9 |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;158.8 |
|  <u>*Cash Flows from Investing Activities*</u> |  |  |  |  |
|  Capital expenditures |  | (35.7) |  | (29.3) |
|  Proceeds on disposal of property, plant and equipment |  | 0.4 |  | 0.3 |
|  Business combinations, net of cash acquired |  | (2.0) |  | (0.2) |
|  Internally developed software |  | (18.6) |  | (12.2) |
|  Net cash used in investing activities |  | (55.9) |  | (41.4) |
|  <u>*Cash Flows from Financing Activities*</u> |  |  |  |  |
|  Non-controlling interest |  | 1 |  | 1.7 |
|  Refinancing costs |  |  |  | (0.3) |
|  Dividend paid |  | (20.8) |  | (19.0) |
|  Issue of treasury stock |  | 0.4 |  | 0.8 |
|  Repurchase of common stock |  | (23.9) |  | (0.7) |
|  Net cash used in financing activities |  | (43.3) |  | (17.5) |
|  Effect of foreign currency exchange rate changes on cash |  | 3.9 |  | 0.2 |
|  Net change in cash and cash equivalents |  | (18.4) |  | 100.1 |
|  Cash and cash equivalents at beginning of period |  | 289.2 |  | 203.7 |
|  Cash and cash equivalents at end of period | $— | 270.8 | $— | 303.8 |

---